Ascentage Pharma Group International (HKG:6855) raised $126.4 million from its US initial public offering of 7,325,000 American depository shares at $17.25 apiece, a Tuesday press release said.
The drugmaker also granted underwriters a 30-day option to buy up to 1,098,750 more ADSs at the IPO price, with underwriting costs deducted.
J.P. Morgan Securities and Citigroup Global Markets served as the joint book-running managers for the offering.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。